Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro

Laboratory Investigation

Volumn 88, Issue 2, 2008, Pages 171-184

  Chakravarti, Arpita ^a,b   Marceau, Andrée Anne ^a   Flamand, Louis ^a   Poubelle, Patrice E ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Apoptosis; Cytokines; HIV 1 gp120; Human T cells; Myeloma cells; Osteoprotegerin; TRAIL

Indexed keywords

ANTIRETROVIRUS AGENT; COLECALCIFEROL; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RITONAVIR; SAQUINAVIR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; MYELOMA CELL; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA EXTRACTION; RNA PURIFICATION; WESTERN BLOTTING;

ANTIBODIES; ANTIGENS, CD3; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHOLECALCIFEROL; CULTURE MEDIA, CONDITIONED; CYTOKINES; DOWN-REGULATION; HIV ENVELOPE PROTEIN GP120; HIV PROTEASE INHIBITORS; HUMANS; OSTEOPROTEGERIN; TIME FACTORS; UP-REGULATION;

EID: 38549145065     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700701     Document Type: Article

References (64)

1. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-14367.
2. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
3. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
4. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
5. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002;46:1926-1936.
6. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
7. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080.
8. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
9. Yun TJ, Tallquist MD, Aicher A, et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001;166:1482-1491.
10. Holen I, Croucher PI, Hamdy FC, et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62:1619-1623.
11. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-20962.
12. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-916.
13. Herbeuval JP, Hardy AW, Boasso A, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005;102:13974-13979.
14. Morel J, Audo R, Hahne M, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005;280:15709-15718.
15. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003;107:2250-2256.
16. Theoleyre S, Kwan Tat S, Vusio P, et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun 2006;347:460-467.
17. Zauli G, Corallini F, Bossi F, et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007;110:536-543.
18. Vanderborght A, Linsen L, Thewissen M, et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 2004;31:1483-1490.
19. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002;46:1744-1753.
20. Colucci S, Brunetti G, Rizzi R, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 2004;104:3722-3730.
21. Horwood NJ, Elliott J, Martin TJ, et al. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001;166:4915-4921.
22. Mirosavljevic D, Quinn JM, Elliott J, et al. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 2003;18:984-993.
23. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-335.
24. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97:77-89.
25. Grassi J, Roberge CJ, Frobert Y, et al. Determination of IL1 alpha, IL1 beta and IL2 in biological media using specific enzyme immunometric assays. Immunol Rev 1991;119:125-145.
26. Morinaga T, Nakagawa N, Yasuda H, et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis- inhibitory factor. Eur J Biochem 1998;254:685-691.
27. Bizzarri C, Shioi A, Teitelbaum SL, et al. Interleukin-4 inhibits bone resorption and acutely increases cytosolic Ca2+ in murine osteoclasts. J Biol Chem 1994;269:13817-13824.
28. Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol 1996;157:936-940.
29. Schneeweis LA, Willard D, Milla ME. Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 2005;280:41155-41164.
30. Capon DJ, Ward RH. The CD4-gp120 interaction and AIDS pathogenesis. Annu Rev Immunol 1991;9:649-678.
31. Su SB, Ueda H, Howard OM, et al. Inhibition of the expression and function of chemokine receptors on human CD4+ leukocytes by HIV-1 envelope protein gp120. Chem Immunol 1999;72:141-160.
32. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003;278:48251-48258.
33. Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002;100:4615-4621.
34. Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003;19:849-861.
35. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004;86:269-279.
36. Kanamaru F, Iwai H, Ikeda T, et al. Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells. Immunol Lett 2004;94:239-246.
37. Mirandola P, Ponti C, Gobbi G, et al. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004;104:2418-2424.
38. Tsai HF, Lai JJ, Chou AH, et al. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus. Arthritis Rheum 2004;50:629-639.
39. Weitzmann MN, Cenci S, Rifas L, et al. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 2001;16:328-337.
40. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88-93.
41. Fujita T, Matsui T, Nakao Y, et al. Cytokines and osteoporosis. Ann NY Acad Sci 1990;587:371-375.
42. Takayanagi H, Ogasawara K, Hida S, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFNgamma. Nature 2000;408:600-605.
43. Shinoda K, Sugiyama E, Taki H, et al. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone 2003;33:711-720.
44. Wyzga N, Varghese S, Wikel S, et al. Effects of activated T cells on osteoclastogenesis depend on how they are activated. Bone 2004;35:614-620.
45. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007;109:3839-3848.
46. Wang R, Zhang L, Zhang X, et al. Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. Eur J Immunol 2002;32:1090-1098.
47. Kaplan MJ, Ray D, Mo RR, et al. TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 2000;164:2897-2904.
48. Ursini-Siegel J, Zhang W, Altmeyer A, et al. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol 2002;169:5505-5513.
49. Lubberts E, Joosten LA, Chabaud M, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105:1697-1710.
50. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001;107:1375-1385.
51. Bendixen AC, Shevde NK, Dienger KM, et al. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 2001;98:2443-2448.
52. Josien R, Wong BR, Li HL, et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162:2562-2568.
53. Relic B, Guicheux J, Mezin F, et al. Il-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. J Immunol 2001;166:2775-2782.
54. Meyaard L, Otto SA, Keet IP, et al. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood 1994;84:4262-4268.
55. Oyaizu N, Chirmule N, Kalyanaraman VS, et al. Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA. Proc Natl Acad Sci USA 1990;87:2379-2383.
56. Trofimov S, Pantsulaia I, Kobyliansky E, et al. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/ macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 2004;150:305-311.
57. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 2001;145:685-690.
58. Chan BY, Buckley KA, Durham BH, et al. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem 2003;49:2083-2085.
59. Webb NJ, Bottomley MJ, Watson CJ, et al. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998;94:395-404.
60. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. Aids 2001;15:1731-1733.
61. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Aids 2000;14:F63-F67.
62. Lum JJ, Schnepple DJ, Badley AD. Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. Aids 2005;19:1125-1133.
63. Herbeuval JP, Boasso A, Grivel JC, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005;105:2458-2464.
64. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005;90:6323-6331.